LC-MS/MS method for the simultaneous quantification of intestinal CYP and UGT activity

Area of Science:

• Pharmacology
• Biochemistry
• Analytical Chemistry

Background:

• Orally administered drugs undergo first-pass metabolism in the liver and intestine by cytochrome P450 (CYP) and uridine 5'-diphospho-glucuronosyltransferases (UGT) enzymes.
• Intestinal enzyme activity is poorly understood due to limited tissue availability and low microsomal protein content, complicating kinetic parameter determination.

Purpose of the Study:

• To develop a sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) method for simultaneous quantification of key CYP and UGT metabolites.
• To enable the determination of enzyme kinetic parameters for clinically relevant intestinal biotransformation enzymes.

Main Methods:

• Simultaneous quantification of six metabolites (4-hydroxydiclofenac, 5-hydroxyomeprazole, dextrorphan, 1-hydroxymidazolam, ezetimibe glucuronide, naloxone glucuronide) using LC-MS/MS.
• Method validation according to bioanalytical guidelines for linearity, accuracy, precision, stability, recovery, and matrix effects.
• Application to pooled human jejunal microsomes to determine enzyme kinetic parameters (K_M and V_max).

Main Results:

• A validated LC-MS/MS assay was developed, capable of quantifying analytes in the range of 1-200 nmol/L.
• The method successfully determined Michaelis-Menten kinetic parameters (K_M and V_max) for all monitored metabolites in human jejunal microsomes.
• Metabolite formation followed Michaelis-Menten kinetics, confirming the utility of the developed assay.

Conclusions:

• The developed LC-MS/MS method is sensitive and suitable for characterizing enzymatic activity in the human intestine.
• This assay provides a valuable tool for gaining precise insights into the intestinal contribution to first-pass drug metabolism.
• Improved understanding of intestinal drug metabolism can lead to more accurate predictions of oral drug efficacy and reduced inter-individual variability.